Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 405 Documents

1 2 3 4 5

Quality of Life and Adherence to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia Patients at Dharmais Cancer Hospital Jakarta Nisha Virginia; Maksum Radji; Lucia Rizka Andalucia
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Quality of life and adherence to long-term imatinib mesylate (IM) therapy is a major factor in achieving therapeutic effects in patients with chronic myeloid leukemia (CML). However, the data of the quality of life and adherence level is inconsistent in various studies and is also not fully understood yet in Indonesia. Methods: This is an observational study (single-centered) using a cross-sectional design. CML patients older than 18 years old with National Health Insurance (JKN) at the Dharmais Cancer Hospital (RSKD) Jakarta who used IM for at least one month were tested using the Medication Adherence Questionnaire (MAQ) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) from March to April 2020.Result: A total of 50 CML patients were included in the study (male: female ratio = 1.08: 1), had a good median score of global health status/QoL, and had a good function and symptom scales, except for the fatigue symptom scale (median: 33.33; 25th percentile - 75th percentile: 11.11– 44.44). The patient adherence rate was dominated by adherent patients (20/50; 40.0%). Comparative analysis revealed that the scale of QoL (p = 0.028) and fatigue (p = 0.094) variables showed statistically significant differences between adherent and non-adherent subjects.Conclusions: This study showed that two-fifth of patients were considered to be non-adherent. Adherent patients were known to have higher QoL than non-adherent patients. Meanwhile, patients with severe symptoms of fatigue were found to be non-adherent to IM therapy.

Dari Redaksi Redaksi Redaksi
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v3i1.62

Selaku Pemimpin Redaksi Indonesian Journal of Cancer, kami mengucapkan puji syukur ke hadirat Allah SWT, sehubungan dengan terjalinnya kerjasama antara Rumah Sakit Kanker Dharmais dengan Jurnal Kedokteran Indonesia Medika dalam penerbitan Indonesian Journal of Cancer.Sebenarnya, Indonesian Journal of Cancer telah dipublikasikan oleh Rumah Sakit Kanker Dharmais sejak dua tahun yang lalu dan diterbitkan sendiri oleh RS Kanker Dharmais. Namun, mulai penerbitan tahun 2009 ini, Journal of Cancer bekerja sama dengan Jurnal Kedokteran Indonesia Medika. Dengan kerjasama ini diharapkan jadwal terbit Indonesian Jounal of Cancer menjadi lebih tepat dan jangkauan distribusinya menjadi lebih luas. Meskipun demikian, hak penerbitan sepenuhnya milik RS Kanker Dharmais. Medika hanya terlibat dalam editing bahasa, lay out, cetak, dan distribusi.Ketepatan jadwal terbit dan jangkauan distribusi yang lebih luas merupakan hal positif yang mendukung upaya kami dalam menyebarluaskan informasi tentang kanker kepada seluruh masyarakat Indonesia dan komunitas yang peduli terhadap masalah kanker. Penerbitan Indonesian Journal of Cancer ini merupakan bagian dari rangkaian kompleks dari keinginan kami membangun Pusat Kanker Nasional.Kami yakin Indonesian Journal of Cancer akan mengalami kemajuan yang pesat, terlebih dengan kerja sama ini, mengingat naskah yang akan dimuat adalah naskah-naskah yang merupakan hasil penelitian dengan metode ilmiah yang benar dan secara ilmiah dapat dipertanggungjawabkan. Naskah yang dimuat dalam jurnal ini adalah hasil pemikiran dari para dokter dan peneliti kesehatan di seluruh Indonesia. Untuk itu, kami akan sangat menghargai keterlibatan komunitas peneliti herbal, komunitas onkologi sosial, dan komunitas pengobatan komplementer terkait di bidang kanker untuk memanfaatkan dan menyebarkan informasi mengenai kanker melalui jurnal ini dengan mengirimkan tulisan-tulisan ilmiah.Akhirnya, kami mengucapkan terima kasih kepada Jurnal Kedokteran Indonesia Medika yang telah bersedia melakukan kerjasama dengan kami. Kami yakin kerjasama ini juga akan meningkatkan mutu Indonesian Journal of Cancer dalam menyajikan karya ilmiah kepada para pembaca, dengan membuat Indonesian Journal of Cancer menjadi bacaan ilmiah yang enak dibaca dan mudah dipahami.Semoga kerjasama ini bisa berjalan dengan baik. Amin.

Batasan Prostate Specific Antigen (PSA) pada Pasien Kanker Prostat untuk Memprediksi Metastasis ke Tulang di Rumah Sakit Sardjito, Yogyakarta AHMAD SULAIMAN LUBIS
Indonesian Journal of Cancer Vol 8, No 4 (2014): Oct - Dec 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

The object of this study to establish a serum PSA cut-off value to predict the presence of bone metastasis in prostate cancer. Methods: Consecutive patients diagnosedwith prostate cancer were retrospectively analyzed. Patients had received bone scintigraphy and had their PSA concentration measured. The proper cut-off value was established based on statistical analysis in order to predict the possibility of bone metastasis among them. Results: eighty-three consecutive patients with prostate cancer were enrolled, and 55 patients (66%) with bone metastasis confirmed by scintigraphic findings. A serum PSA concentration of 17.65 ng/ml gave the best sensitivity (78.33%) and specificity (65.21%). The PPV and NPV were 85.45% and 53.57%, respectively (p<0.05) Conclusion: a cut-off value of 17.65 ng/ml appears to be an appropriate benchmark for stratifying metastatic bone disease in prostate cancer patientssuch that if a patient with newly diagnosed prostate cancer and without any skeletal symptoms has a serum PSA concentration of less than 17.65 ng/ml,we suggest that they would not need to undergo bone scintigraphy.

The Role of Family Meeting In Dealing With Rejection Towards Hospital Discharge of Terminally Ill Cancer Patients Maria Witjaksono; Dwi Yatiningsih; Hesti Widaretno; Rani Asdiniah; Ame Ame
Indonesian Journal of Cancer Vol 12, No 2 (2018): April-June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Rejection towards discharge planning of terminally ill patients and the role of family meetings to overcome such issue has not been evaluated. The aims of this study were to identify who and the reasons of rejection, to evaluate the effectiveness of family meetings, and to assess the important aspects in preparing homecare.Methods: This is an interventional study using queasy-experimental design. Samples of the study were family members of terminally ill patients who refused patient discharge from 1st of May to 31st of October 2016. Paired-Sample T-test was applied to analyze the result. Result: Rejections of discharge planning was mostly by the families. The most reason of rejection was lack of knowledge and skills in taking care of the terminally ill patients (40%). Family meetings solved the problem of rejection. The total score of 10 aspects needed in taking care of terminally ill patients was significantly increased (p=0.000). Conclusion: Family meetings effectively changed the attitude towards hospital discharged

Comparison Between HE4, CA-125, and Combination of Both HE4 and CA-125 as Tumor Markers for Epithelial Ovarian Carcinoma Patients PUNGKY MULAWARDHANA; BRAHMANA ASKANDAR; SOEHATNO -
Indonesian Journal of Cancer Vol 6, No 2 (2012): Apr - Jun 2012
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v6i2.166

Tujuan: Mengetahui dan membandingkan sensitivitas, spesifisitas, Positive Predictive Value, dan Negative Predictive Value antara HE4, CA-125, serta kombinasi HE4 dan CA-125 sebagai tumor marker pada pasien kanker ovarium tipe epitel. Mengetahui adanya korelasi antara kadar HE4 dengan kadar CA-125 serum pada pasien tumor ovarium.Metode penelitian dan tempat: Penelitian ini merupakan studi observasional analitik dengan cross-sectional, dilaksanakan di poli, ruang kandungan, dan Laboratorium Patologi Klinik RSU dr. Soetomo, sert laboratorium Prodia. Sampel dan alur penelitian: Terdapat 53 pasien dengan tumor ovarium yang dioperasi di RSU dr. Soetomo antara Februari sampai Mei 2011 yang memenuhi kriteria inklusi dan ekslusi. Terhadap masing-masing pasien dilakukan pemeriksaan HE4 dan CA-125 pada 1 hari sebelum operasi. Setelah hasil PA selesai, didapatkan 11 pasien yang mengalami drop out, 42 pasien lainnya kami masukkan dalam analisa penelitian dengan rincian 17 pasien kanker ovarium tipe epitel dan 25 pasien dengan tumor jinak ovarium. Peneliti berusaha mengetahui dan membandingkan sensitivitas, spesifisitas, Positive Predictive Value, dan Negative Predictive Value antara HE4, CA-125, serta kombinasi HE4 dan CA-125 sebagai tumor marker pasien kanker ovarium tipe epitel.Hasil penelitian: Analisis statistik Mc Nemar menunjukan kadar CA-125 serum memiliki perbedaan yang bermakna dengan hasil PA (p = 0,004), sedangkan kadar HE4 serum (p = 1,000) dan kombinasi kadar HE4 & CA-125 serum (p = 0,344) tidak memiliki perbedaan yang bermakna dengan hasil PA dalam menentukan diagnosis kanker ovarium. Spesifisitas kombinasi HE4 dan CA-125 (88,00%) lebih baik dari HE4 (80,00%) maupun CA-125 (20,00%). Sensitivitas HE4 (76,47%) lebih baik dari CA-125 (70,59%) maupun kombinasi HE4 dan CA-125 (58,82%). Positive predictive value kombinasi HE4 dan CA-125 (76,92%) lebih baik dari HE4 (72,22%) maupun CA-125 (37,50%). Negative predictive value HE4 (83,33%) lebih baik dari kombinasi HE4 dan CA-125 (75,86%) maupun CA-125 (50,00%). Uji korelasi dari Pearson menilai semua pasien sampel tumor ovarium mendapatkan adanya korelasi kadar HE4 serum dengan CA-125 serum, nilai r = 0,453 (p = 0,003).Kesimpulan: Kombinasi HE4 dan CA-125 memiliki nilai diagnostik lebih tinggi dibandingkan dengan HE4 tunggal dan CA-125 tunggal sebagai tumor marker kanker ovarium tipe epitel. Terdapat korelasi antara kadar CA-125 serum dengan kadar HE4 serum pada pasien tumor ovarium, walaupun tidak ada hubungan patofisiologi antara kedua tumor marker tersebut.Kata kunci: HE4, CA-125, sensitivitas, spesifisitas, positive predictive value, negative predictive value, kanker ovarium tipe epitel, tumor jinak ovarium

Sarcopenic Obesity in Cancer Patients: Focus on Pathogenesis Wilson Matthew Raffaello; Andree Kurniawan
Indonesian Journal of Cancer Vol 14, No 3 (2020): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Sarcopenic obesity is an emerging problem in cancer patients. However, this is often difficult to diagnose without the measurement of body composition. Sarcopenic obesity is associated with increased mortality, chemo-toxicity, and other complications in cancer patients. Until now, there is scarce information about sarcopenic obesity in the cancer population.Method: We identified 1955 articles related to sarcopenic obesity in adult cancer patients using PubMed, PubMed Central, and Cochrane Library databases from January 1, 1989, until January 1, 2020. Firstly, we screened the titles and abstracts which mentioned sarcopenic and obesity, especially in pathogenesis. 29 articles could proceed to the next step; then, they were screened for the full text. All steps were reviewed by two authors.Results: At last, they were 9 articles included. Sarcopenic obesity is defined as the coexistence of sarcopenia and obesity, an increase in fat mass in the body. Sarcopenic obesity carried cumulative risks from each of the two individual body compositions. CT-scan offers the highest available precision in determining body composition parameters, especially in the cancer population. Multiple causes and interactions between hormonal changes, aging, disuse, neuronal, poor nutrition, physical inactivity, and low-grade inflammation played roles. Sarcopenic obesity is associated with chemotherapy toxicity. High protein intake should be initiated to ensure adequate protein intake. Resistance training is beneficial in improving muscle mass and strength by focusing on strength training, flexibility, and balance.Conclusions: Sarcopenic obesity is an emerging problem but is often neglected. Further research needs to be conducted especially in explaining the pathogenesis of sarcopenic obesity. The combination of physical exercise and diet modification is the best management to improve sarcopenia obesity in cancer patients.

Kriteria Diagnosis Kanker Paru Primer Berdasarkan Gambaran Morfologi pada CT Scan Toraks Dibandingkan dengan Sitologi Aziza Icksan; Faisal -; Elisna -; Pudjo Astowo; Heriawaty Hidayat; Joedo Prihartono
Indonesian Journal of Cancer Vol 2, No 1 (2008): Jan - Mar 2008
Publisher : National Cancer Center - Dharmais Cancer Hospital

Menetapkan komponen gambaran morfologi kanker paru primer pada CT scan toraks yang dapat dipakai sebagai kriteria diagnosis. Penelitian ini menggunakan desain cross sectional. Dalam kurun waktu Desember 2006 - Mei 2007 di RS. Persahabatan Jakarta dilakukan pemeriksaan CT scan toraks terhadap 28 pasien dengan gambaran klinis diduga kanker paru primer. DinilailO gambaran morfologi kanker paru pada CT scan toraks, setiap gambaran morfologi kanker dibandingkan dengan hasil sitologi CT guided TTNA sebagai baku emas. Terdapat 7 komponen morfologi kanker paru primer pada CT scan toraks yang mempunyai sensitivitas yang tinggi dalam diagnosis yaitu: ukuran tumor > 3 cm sensitivitas 95,7%, penyangatan s24 HU sensitivitas 82,6%, tepi irregular-spiculated sensitivitas 78,3%, lobulated sensitivitas 73,9%, air bronchograms sensitivitas 69,6%, ground glass opacity sensitivitas 65,2 % dan densitas heterogen sensitivitas 65,2%.Komponen morfologi ukuran tumor > 3 cm, penyangatan 24 HU, tepi irregular spiculated, lobulated, air bronchograms, ground glass opacity dan densitas heterogen mempunyai sensitivitas yang tinggi serta dapat dipakai sebagai kriteria diagnosis kanker paru primer pada CT scan toraks.Kata kunci: morfologi, kanker paru primer, CT scan toraks

Patogenesis, Diagnosis, dan Penatalaksanaan Tromboemboli Vena pada kanker Andree Kurniawan
Indonesian Journal of Cancer Vol 7, No 3 (2013): Jul - Sep 2013
Publisher : National Cancer Center - Dharmais Cancer Hospital

Tromboemboli vena sering terjadi pada pasien kanker. Kejadian tromboemboli vena memiliki morbiditas dan mortalitas yang bermakna pada pasien kanker. Studi terbaru menunjukkan pemahaman yang lebih baik terkait faktor risiko klinis dan biomarker biologis yang dapat menjelaskan patogenesisnya menjadi lebih mudah dimengerti. Model prediksi risiko telah dihasilkan untuk menstratifikasi faktor risiko tromboemboli vena multipel pada pasien kanker. Profilaksis terjadinya trombosis dengan unfractioned heparin atau low-molecular-weight heparin (LMWHs) telah diperlihatkan aman dan efektif pada pasien risiko tinggi. Tata laksana tromboemboli vena pada kanker memerlukan antikoagulan jangka panjang dengan LMWH atau antikoagulan oral.Kata kunci: kanker, tromboemboli vena

Stereotactic Radiosurgery in Recurrent Brain Metastases After Prior Radiosurgery: A Case Report and Review of Literature HENRY KODRAT; RIMA NOVIRIANTHY
Indonesian Journal of Cancer Vol 10, No 4 (2016): October - December 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTPreviously, all brain metastasis has been treated with whole brain radiotherapy and the survival is poor. Recently, the development of stereotactic radiosurgery (SRS) provides comparable efficacy with low toxicity, and in several cases have a better survival compared to historical data. We conducted a case review in brain metastasis, which has been treated with SRS previously and experienced distant brain recurrence, then re-treated with SRS.ABSTRAKDahulu, semua metastasis otak ditangani dengan modalitas radiasi seluruh otak dan memiliki kesintasan yang tidak terlalu baik. Saat ini berkembang modalitas stereotactic radiosurgery (SRS). SRS memberikan efektivitas yang sebanding dengan toksisitas yang rendah dan pada beberapa kasus memiliki kesintasan yang lebih baik dibandingkandata sebelumnya. Berikut adalah tinjauan kasus metastasis otak dengan penanganan SRS sebelumnya dan mengalami kekambuhan di lokasi lain pada otak, kemudian ditatalaksana ulang dengan SRS.

Morbiditas dan Mortalitas Dini Pasca-Sistektomi Radikal pada Kanker Buli-Buli di RSCM, 1999 - 2009 ILHAM WAHYUDI MASFAR; CHAIDIR ARIEF MOCHTAR; RAINY UMBAS
Indonesian Journal of Cancer Vol 4, No 4 (2010): Oct - Dec 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i4.118

Purpose: to evaluate early morbidity and mortality rate after radical cystectomy and urinary diversion also the prognostic factor(s). Material and method: we retrospectively collected data from medical records patient who underwent radical cystectomy and urinary diversion at RS. Cipto Mangunkusumo during 1999 2009 period.Descriptive evaluation was done on number and type of morbidity and mortality. Modified Clavien System was used as standarized complication report method. Prognostic factors were analyzed.Result: there was 62.9% of early morbidity rate, 11% of early mortality rate, 40% of major morbidity according modified Clavien System. None of prognostic factors were statistically significant.Conclusion: early morbidity rate was similar to other reports. But rate of early major morbidity and mortality were higher. This is probably due to higher number of preoperative comorbidities, more advanced tumor stage, and low hospital volume for this particular procedure compared to others.

Page 1 of 41 | Total Record : 405

1 2 3 4 5

Filter by Year

2007 2023

Filter By Issues

All Issue Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA